Andrew Aronsohn, MD, is a specialist in the diagnosis and treatment of liver disease, including medical management of liver transplantation.
He is an associate professor at the University of Chicago Medicine Center for Liver Diseases, a multidisciplinary center that is nationally known for its research discoveries and treatment innovations related to liver diseases and transplantation. He is also a faculty member at the MacLean Center for Clinical Medical Ethics.
Dr. Aronsohn’s research interests involve investigation of ethical issues surrounding hepatitis C therapy, which include fair distribution of resources and linkage to care. He leads the hepatitis curriculum of ECHO Chicago, which aims to educate and empower primary care providers to effectively manage hepatitis C in a local primary care setting.
Dr. Aronsohn serves as a committee member on the National Academy of Sciences report for hepatitis B and C elimination as well as the AASLD/IDSA guidance for hepatitis C treatment.
Innovative strategies to enhance access to HCV therapy.
Innovative strategies to enhance access to HCV therapy. Lancet. 2025 May 17; 405(10491):1722-1723.
PMID: 40347966
International Travel for Organ Transplantation: Provider and Patient Perspectives.
International Travel for Organ Transplantation: Provider and Patient Perspectives. Transplant Direct. 2024 Aug; 10(8):e1686.
PMID: 39035117
Ethics and downstream effects of travel for transplant in the United States.
Ethics and downstream effects of travel for transplant in the United States. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 23(1):e0242.
PMID: 38912002
Fecal metabolite profiling identifies liver transplant recipients at risk for postoperative infection.
Fecal metabolite profiling identifies liver transplant recipients at risk for postoperative infection. Cell Host Microbe. 2024 01 10; 32(1):117-130.e4.
PMID: 38103544
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 11; 8(11):2033-2049.
PMID: 37845315
HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago.
HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago. J Public Health (Oxf). 2022 12 01; 44(4):891-899.
PMID: 34156077
Identifying Stigma as a Key Initial Step to Equitable Hepatitis C Virus Care.
Identifying Stigma as a Key Initial Step to Equitable Hepatitis C Virus Care. JAMA Netw Open. 2022 12 01; 5(12):e2246610.
PMID: 36515956
Reply.
Reply. Hepatology. 2022 04; 75(4):1055-1056.
PMID: 34859470
HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago.
Tilmon S, Aronsohn A, Boodram B, Canary L, Goel S, Hamlish T, Kemble S, Lauderdale DS, Layden J, Lee K, Millman AJ, Nelson N, Ritger K, Rodriguez I, Shurupova N, Wolf J, Johnson D. HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago. J Public Health (Oxf). 2021 Jun 22.
PMID: 34156077
"Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era.
"Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. Transplant Direct. 2021 Jul; 7(7):e707.
PMID: 34124343